Application of in vivo micro-computed tomography in the temporal characterisation of subchondral bone architecture in a rat model of low-dose monosodium iodoacetate-induced osteoarthritis
© Mohan et al.; licensee BioMed Central Ltd. 2012
Received: 23 February 2011
Accepted: 21 December 2011
Published: 21 December 2011
Osteoarthritis (OA) is a complex, multifactorial joint disease affecting both the cartilage and the subchondral bone. Animal models of OA aid in the understanding of the pathogenesis of OA and testing suitable drugs for OA treatment. In this study we characterized the temporal changes in the tibial subchondral bone architecture in a rat model of low-dose monosodium iodoacetate (MIA)-induced OA using in vivo micro-computed tomography (CT).
Male Wistar rats received a single intra-articular injection of low-dose MIA (0.2 mg) in the right knee joint and sterile saline in the left knee joint. The animals were scanned in vivo by micro-CT at two, six, and ten weeks post-injection, analogous to early, intermediate, and advanced stages of OA, to assess architectural changes in the tibial subchondral bone. The articular cartilage changes in the tibiae were assessed macroscopically and histologically at ten weeks post-injection.
Interestingly, tibiae of the MIA-injected knees showed significant bone loss at two weeks, followed by increased trabecular thickness and separation at six and ten weeks. The trabecular number was decreased at all time points compared to control tibiae. The tibial subchondral plate thickness of the MIA-injected knee was increased at two and six weeks and the plate porosity was increased at all time points compared to control. At ten weeks, histology revealed loss of proteoglycans, chondrocyte necrosis, chondrocyte clusters, cartilage fibrillation, and delamination in the MIA-injected tibiae, whereas the control tibiae showed no changes. Micro-CT images and histology showed the presence of subchondral bone sclerosis, cysts, and osteophytes.
These findings demonstrate that the low-dose MIA rat model closely mimics the pathological features of progressive human OA. The low-dose MIA rat model is therefore suitable to study the effect of therapeutic drugs on cartilage and bone in a non-trauma model of OA. In vivo micro-CT is a non-destructive imaging technique that can track structural changes in the tibial subchondral bone in this animal model, and could also be used to track changes in bone in preclinical drug intervention studies for OA treatments.
Osteoarthritis (OA) is generally a slow progressive joint disease characterized by loss of articular cartilage, subchondral bone sclerosis, cysts, and osteophyte formation . The etiopathology of OA remains obscure and currently there are no pharmacological interventions available to halt or reverse the progression of OA. Animal models of OA are of considerable importance as they are not only useful to study the pathogenesis and progression of OA, but also to evaluate suitable therapeutic drugs for OA treatment. Moreover, knowledge of early pathological changes is essential for early treatment options and to develop better therapeutic agents to modify the disease progression.
The monosodium iodoacetate (MIA)-induced OA rat model is a minimally invasive animal model that reproduces cartilage and bone pathology similar to human OA . The onset, progression and severity of OA can be easily controlled in this model by changing the dose of MIA, which makes it useful to study disease progression and the effect of disease modifying osteoarthritis drugs (DMOAD). A dose response study by Guingamp et al. showed that the severity of cartilage degradation depends on the dosage of MIA injected into the knee joint. Higher doses of MIA (up to 3 mg) caused cartilage erosion, sclerosis and exposure of subchondral bone on day 15 post MIA injection, and on day 30 there was complete loss of articular cartilage, with greatly remodelled subchondral bone , whereas, a low-dose of MIA (0.25 mg) induced moderate cartilage damage at 3 weeks . In a pilot study, we evaluated the dose responsiveness of tibial cartilage and subchondral bone to MIA using a high-dose of 2 mg MIA (n = 3) and a low-dose of 0.2 mg MIA (n = 3) in rats. As early as after two weeks, high-dose MIA induced characteristic features of end-stage human OA such as loss of tibial articular cartilage, exposure of subchondral bone, subchondral trabecular bone erosion, cysts and osteophytes. In contrast, these changes were observed only at ten weeks in the low-dose MIA model (Mohan G et al: unpublished observations). The low-dose MIA model, of relatively slow progressing OA, enables in vivo monitoring of tissue-level changes representative of progressive human OA; whereas, in the high-dose model the disease progression is very rapid, which is less suitable for longitudinal monitoring of cartilage and subchondral bone changes.
The tissue-level characterization of animal models of OA has traditionally been done by histological assessment. Developments in X-ray micro-computed tomography (micro-CT) allow in vivo imaging of small animal models, with high spatial resolution and at subsequent time points, to study bone architecture [5–7]. This imaging technique enables non-destructive assessment of the bone both quantitatively and qualitatively. Moreover, the use of a longitudinal study design using in vivo micro-CT allows the quantification of subchondral bone in the same animal over time. Recent studies have used micro-CT to quantify structural changes in the tibial subchondral bone in the MIA rat model; however, those studies have utilized high-dose MIA injections, with the rats examined only at the end point of the studies [8–10]. The temporal changes in the structure of subchondral trabecular bone during the progression of OA in the low-dose MIA model have not been previously described.
The purpose of this study was to characterize the structural changes in the tibial subchondral bone using longitudinal in vivo micro-CT imaging in an animal model that closely mimics human progressive OA. It is hypothesised that low-dose MIA will induce cartilage changes and measurable, progressive tibial subchondral bone changes at two, six, and ten weeks post-injection.
Materials and methods
Animals and OA induction
Twelve 8-week-old male Wistar rats (Animal Resource Center, Canning Vale, WA, Australia), weighing 200 - 230 g at the start of the experiment, were used. They were kept in a sanitary ventilated animal room with controlled temperature (20 to 24°C), a light-dark cycle (12 hour/12 hour) and were fed standard laboratory rodent chow (Specialty Feeds, Glen Forrest, WA, Australia) with water available ad libitum. The rats were acclimatized for one week before the start of the experiment. They were closely monitored and daily clinical record sheets were completed throughout the duration of the study by the animal care facility staff.
On day 0, the rats were anesthetized with an isoflurane/O2 mixture and both their knees were shaved and disinfected with 70% alcohol. Each rat was given a single intra-articular injection of 0.2 mg MIA through the infrapatellar ligament of the right knee. MIA was dissolved in sterile physiologic saline and administered in a volume of 50 μl using a 26-gauge 0.5-inch needle. The left contralateral control knee was injected with 50 μl of sterile physiologic saline.
The hind limbs of all the rats were imaged with high-resolution in vivo micro-CT at two, six, and ten weeks post-MIA injection, which represent early, intermediate, and advanced stages of OA. Double-fluorescent labelling of newly formed bone was achieved by using calcein (5 mg/kg body weight; Sigma-Aldrich, Sydney, NSW, Australia) administered intraperitoneally on day 7 before sacrifice, followed by xylenol orange (90 mg/kg body weight; Sigma-Aldrich, Australia) administered intraperitoneally 2 days before sacrifice. The animal handling and experimental procedures outlined in this study were carried out in accordance with The University of Adelaide Animal Ethics Committee and The Institute of Medical and Veterinary Science Animal Ethics Committee.
In vivo micro-CT imaging
Bone histomorphometric analysis
Subchondral trabecular bone
In the binarized images, the subchondral plate was separated from the trabecular bone of the tibia by using a software kindly provided by Botter et al. . The 3D subchondral plate thickness (Pl.Th, μm) and porosity (volume of the pores in the plate over the total volume of the plate, Pl.Por, %) of the medial and lateral compartments of the tibial subchondral plate were calculated on regions measuring 1.5 mm medio-lateral in width, 2.5 mm in length from the posterior side. For both parameters (Pl.Th and Pl.Por), the data from the medial and lateral compartments were averaged to obtain the value of the total compartment .
At ten weeks post-MIA injection the rats were euthanized with a CO2 overdose and both the right and left tibiae were dissected for macroscopic study. Soft tissues surrounding the tibia were carefully removed to prevent articular cartilage damage. The image of the tibial cartilage was recorded using a fluorescence stereomicroscope (SZX 10, Olympus). With the microscope, the fluorochrome labels calcein and xylenol orange were imaged and recorded. The macroscopic lesions were graded as follows: 0 = normal appearance, 1 = slight yellowish discoloration of the chondral surface, 2 = little cartilage erosions in load-bearing areas, 3 = large erosions extending down to the subchondral bone, and 4 = large erosion with large areas of subchondral bone exposure . Two blinded observers graded the medial and lateral tibial plateaus separately. The scores for the tibiae were combined and the average values were determined for the MIA-injected knee and the control knee.
After imaging, the tibiae (n = 6 rats; tibiae from the other 6 rats were used in another analysis) were fixed in 4% paraformaldehyde, decalcified and embedded in paraffin. Three coronal sections (5 μm thick) 100 μm apart were obtained and stained with 1.5% Safranin O, and 0.02% fast green counter stain. The sections were observed for OA-like features such as surface discontinuity, loss of proteoglycans, disorientation of chondrocytes, subchondral bone sclerosis and presence of cysts and osteophytes.
The Osteoarthritis Research Society International (OARSI) scoring method  was used to grade and stage tibial cartilage in the MIA-injected knee and control knee. For each histological slide, the OA score was obtained by multiplying the grade and stage values. The OA score ranges from 0 (representing no OA activity) to 24 (highest OA degradation).
Serum C-reactive protein (CRP) analysis
Blood samples were obtained by tail venipunture from the MIA-injected rats (n = 6) and a group of age-matched control rats (n = 4, from another non-micro-CT imaging study) under isofluroane anaesthesia. Blood samples were obtained from the rats at pre-injection, two, six, and ten week time points. Serum samples were collected and stored at -80°C until analyzed. Serum levels of CRP, a marker of systemic inflammation, were measured by enzyme-linked immunosorbent assay according to the manufacturer's protocol (Rat CRP ELISA kit, BD Biosciences, San Diego, CA, USA).
The morphometric parameters had a normal distribution (Shapiro-Wilk test, P > 0.05 for all the examined parameters). For each morphometric parameter it was determined whether there was (a) a 'time effect' and (b) a 'time by group interaction effect'. The 'time effect' indicates if there was any change over time within each group (tibia of control and MIA-injected knee) and the 'time by group interaction effect' indicates if the different groups showed different patterns of changes over time. For each tibia, 3D morphometric parameters and serum CRP data sets were examined using analysis of variance for repeated measures (two-way repeated measures ANOVA). If F-values for a given variable were found to be significant, a paired Student's t-test was applied to assess the changes in the morphometric parameters and CRP between the MIA-injected knee and control knee. The P-values were adjusted for repeated comparisons by Holm's Bonferroni stepdown procedure . Similarly, a paired Student's t-test with P-values adjusted for repeated comparison by Holm's Bonferroni stepdown procedure was done to assess changes in each tibia between time points. The overall type I error rate was set at an alpha level of 0.05.
Bone histomorphometric changes
Subchondral trabecular bone
Morphometric parameters of tibial subchondral trabecular bone in the MIA-injected tibiae and in the control tibiae, at 2, 6, and 10 weeks post-MIA injection
Mean ± SD
Mean ± SD
Mean ± SD
Mean ± SD
Mean ± SD
Mean ± SD
BV (mm 3 )
613 ± 97
745 ± 118
1177 ± 211
993 ± 214
1481 ± 271
1179 ± 229
647 ± 120
711 ± 130
1145 ± 168
948 ± 169
1229 ± 133
1205 ± 241
1260 ± 202
1456 ± 239
2322 ± 341
1941 ± 370
2710 ± 326
2384 ± 454
16.8 ± 2.6
20.4 ± 3.2
32.7 ± 6.5
27.5 ± 6.6
39.8 ± 7.7
33.6 ± 7.6
15.1 ± 2.8
16.7 ± 3.0
27.2 ± 3.6
22.2 ± 3.8
29.0 ± 3.2
28.2 ± 6.0
15.9 ± 2.5
18.6 ± 3.0
30.0 ± 4.2
24.8 ± 5.0
34.4 ± 4.8
30.9 ± 6.4
94 ± 5
92 ± 3
124 ± 11
100 ± 9
p < 0.001
149 ± 19
110 ± 12
89 ± 4
87 ± 3
117 ± 9
95 ± 5
128 ± 17
105 ± 8
91 ± 4
90 ± 3
120 ± 9
97 ± 7
p < 0.001
138 ± 18
108 ± 10
1.8 ± 0.3
2.2 ± 0.3
2.5 ± 0.5
2.7 ± 0.5
2.6 ± 0.5
3.1 ± 0.4
1.7 ± 0.3
1.9 ± 0.3
2.2 ± 0.3
2.3 ± 0.3
2.3 ± 0.3
2.7 ± 0.3
1.7 ± 0.2
2.1 ± 0.3
2.3 ± 0.3
2.5 ± 0.4
2.5 ± 0.3
2.9 ± 0.4
270 ± 16
243 ± 17
p < 0.001
240 ± 19
203 ± 24
241 ± 32
207 ± 20
272 ± 16
256 ± 17
250 ± 16
221 ± 14
258 ± 17
223 ± 15
p < 0.001
271 ± 13
250 ± 14
p < 0.001
245 ± 15
212 ± 16
245 ± 22
215 ± 15
At two weeks, no statistically significant difference was observed in Tb.Th in all the three tibial compartments between the MIA-injected knee and control. However, at six and ten weeks, there was a significant increase in Tb.Th in the MIA-injected knee compared to the control knee in the medial (25%, P < 0.001, and 35%, P < 0.01, respectively), lateral (23%, P < 0.01, and 22%, P < 0.05, respectively) and total (24%, P < 0.001, and 29%, P < 0.01, respectively) tibial compartments. The Tb.N was significantly lower in the MIA-injected knee compared to the control knee in all the three tibial compartments at two weeks and in the lateral and total compartments at ten weeks post-MIA injection. At 2 weeks, the Tb.N was reduced by 20% (P < 0.01), 12% (P < 0.05), and 16% (P < 0.01) in the medial, lateral and total compartments, respectively. At six weeks, the Tb.N did not differ significantly between the tibia of the MIA-injected knee and control knee. At 10 weeks, the Tb.N was decreased by 14%, 16% (P < 0.01) and 15% (P < 0.05) in the medial, lateral and total compartments, respectively, when compared to the control knee. The Tb.Sp in the MIA-injected knee was significantly higher than in the control knee at all the three time points, in all the three tibial compartments. At 2 weeks, the Tb.Sp of the MIA-injected knee was increased by 11% (P < 0.001), 6% (P < 0.01) and 8% (P < 0.001) in the medial, lateral and total compartments, compared to control. Similarly, at 6 weeks, in the MIA-injected knee there was an increase of 18%, 13% and 16% (P < 0.01 for all compartments), respectively, and at 10 weeks there was an increase of 16% (P < 0.01), 16% (P < 0.001) and 14% (P < 0.01), in the medial, lateral and total compartments, respectively, compared to control.
Tibial subchondral plate thickness and porosity of the MIA-injected knee and control knee, at 2, 6, and 10 weeks post-MIA injection.
Subchondral Plate Thickness, Pl.Th (μm)
Subchondral Plate Porosity, Pl.Por (%)
OA - CTL
OA - CTL
OA - CTL
114 ± 7
105 ± 7
101 ± 6
109 ± 7
107 ± 4
107 ± 8
146 ± 32
119 ± 32
130 ± 17
120 ± 26
138 ± 23
118 ± 26
p < 0.001
p < 0.001
181 ± 27
175 ± 31
166 ± 18
178 ± 24
177 ± 19
177 ± 25
Qualitative subchondral bone changes
In the MIA-injected knee, the subchondral bone was sclerosed and exposed in the medial tibial plateau beneath the areas of cartilage damage. Focally extensive areas of subchondral bone marrow were replaced by loosely arranged spindle cells (fibrotic bone marrow) (Figure 9D). At six and ten weeks, the subchondral plate was breached in focal areas, with cartilage damage and proliferating chondrocytes at ten weeks suggesting fibrocartilage repair (Figure 5B). In four out of six rats, subchondral bone cysts were observed below the articular surface. These cysts were present in the sites of severe bone resorption causing bone marrow lesions. The subchondral bone cysts were surrounded by sclerotic bone with fibrous tissue often containing debris of necrotic bone trabeculae. Some trabeculae adjacent to the sites of bone resorption were lined by a row of large reactive osteoblasts (Figure 5D). Marginal tibial osteophytes were observed in all the rats at ten weeks post-MIA injection of the knee. Bone marrow spaces filled with fibrous cells were observed in these osteophytes (Figure 6D).
Serum CRP levels
The serum CRP levels were not significantly different between the MIA-injected rats and control rats at any time-point. In addition, there was no significant difference between time points for each of the two groups. In the MIA-injected rats, the mean ± SD concentrations were as follows: 204 ± 32 μg/ml, 201 ± 44 μg/ml, 190 ± 50 μg/ml, and 202 ± 7 μg/ml at pre-injection, 2, 6 and 10 weeks, respectively. For the control group the mean ± SD concentrations were as follows: 172 ± 42 μg/ml, 186 ± 24 μg/ml, 181 ± 34 μg/ml, and 212 ± 9 μg/ml at pre-injection, 2, 6 and 10 weeks, respectively.
This study characterized the temporal changes in the tibial subchondral bone architecture in a low-dose MIA-induced OA rat model using in vivo micro-CT. The strength of this study is the use of a longitudinal study design, which enabled the quantitative and qualitative assessment of OA-related changes in the tibial subchondral trabecular bone within the same animal over time. This is the first in vivo study to examine subchondral trabecular bone changes over time revealing a significantly lower bone volume fraction at two weeks, followed by subchondral bone sclerosis at six and ten weeks, in the low-dose MIA-induced OA rat model.
The initial bone loss observed at two weeks, followed by sclerosis during the progression of OA is consistent with findings in other animal models of OA, such as the anterior cruciate ligament transection (ACLT) in rats , the canine model  and the collagenase-induced murine model, and to human OA . This initial bone loss observed at two weeks in the low-dose MIA rat model could have been due to transient unloading of the MIA-injected knee. Previously, it had been shown that MIA injection in the rat knee joint leads to concentration related transient changes in hind paw weight distribution [3, 19]. In the MIA-injected knee, Tb.N was decreased and Tb.Sp was increased relative to the control tibia at all time points, which suggests an active process of subchondral trabecular bone erosion. Together with the increases in Tb.Th found at weeks six and ten, these findings indicate that subsequent increased bone formation in the MIA-injected knee resulted from subchondral trabecular bone thickening. This strongly suggests a mechanism for bone remodelling/modelling in the subchondral trabecular bone in OA .
It should also be noted that over time the tibial subchondral BV, BV/TV, Tb.Th, Tb.N and Pl.Th increased, whereas the Tb.Sp decreased, in both the MIA-injected knee and the control knee (Figure 3). This is in part due to the normal growth of the rats at baseline, reaching skeletal maturity. Similar age-related changes (increases) in volumetric bone mineral density (vBMD) due to the effect of normal animal growth have been reported in the high-dose MIA rat model  and ACLT model . However, in our study the use of the contralateral tibia as an internal control eliminates inter-animal variability for age-related changes and weight.
Pathologic subchondral plate changes are recognized as a characteristic feature of OA. Previous studies have looked at the subchondral plate changes in animal models of OA such as dogs, mice, cynomolgus macaques, guinea pigs, and rabbits but not in rat models of OA. Early subchondral plate thinning of the OA knee followed by an increase in thickness has been reported in the ACLT animal models of OA [17, 23, 24] and collagen induced OA in mice [13, 18]. However, in the low-dose MIA-injected OA animal model, we found an increase in the subchondral plate thickness in the medial tibial plateau at two and six weeks post injection. Such an early increase in the subchondral plate thickness has been previously reported in other animal models of OA such as rabbits  and guinea pigs , and in studies of hand and knee OA patients . This early increase in subchondral plate thickness observed in the MIA-injected knee could be due to altered loading of the affected knee joint. The thickened subchondral bone could also be associated with progression of cartilage degeneration. In our study, at ten weeks we did not observe the expected increase in the tibial subchondral plate thickness in the MIA-injected knee compared to the control. This could be due to the tibial subchondral plate breach observed in the MIA-injected knee. The increased porosity of the tibial subchondral plate in the MIA-injected knee compared to the control is in line with previous literature [23, 24]. This increase in porosity is believed to play an important role in the communication between bone and cartilage during the pathogenesis of OA.
In the present study, the involvement of the subchondral trabecular bone structure after induction of OA using low-dose MIA is clearly shown in a temporal sequence. The two, six and ten week time points were chosen to characterize early, intermediate and advanced OA-related changes in the bone. Because previous studies using the high-dose MIA rat model have reported the involvement of subchondral bone as early as two weeks after injection , two weeks was chosen as the early time point in this study. A minimum of four weeks interval is recommended between scans , hence, six and ten weeks were chosen as subsequent time points. Given the paired study design, where the contralateral knee was used as an internal control, we prioritized the capture of early subchondral bone changes at two weeks over acquiring baseline data.
Qualitative analysis of micro-CT images revealed subchondral trabecular bone sclerosis at six and ten weeks post-MIA injection in the medial tibial plateau (Figure 4). This thickening of the subchondral trabecular bone was detected by the significant increases in trabecular thickness at six and ten weeks. Subchondral trabecular bone loss together with subchondral bone sclerosis suggests increased osteoclastic and osteoblastic activity that leads to altered subchondral bone remodelling .
In our study, micro-CT imaging revealed subchondral plate breach at six and ten weeks post-MIA injection. This was observed in areas of cartilage damage in all the rats (Figure 5A, B). In the weight bearing regions of the medial tibial plateau where the cartilage damage was severe, microfractures were observed in the subchondral plate that exposed the subchondral bone marrow to the joint cavity. This could potentially allow synovial fluid to enter the subchondral bone that triggers cystic cavity formation . Another study suggests that the increased pressure between the delaminated joint surface leads to joint erosion, with synovial breach as a secondary event . A recent study of human OA suggests that cysts may develop in pre-existing bone marrow lesions . The subchondral plate breach also suggests fibrocartilage repair, which could be seen as a discontinuity of the articular bony plate . Januz et al. have previously reported subchondral plate breach and its association with subchondral bone sclerosis and cyst formation in the MIA rat model . In our study, 67% of the rats showed subchondral bone cysts in areas of bone resorption (Figure 5C, D).
Another hallmark feature of OA is the presence of osteophytes. In our study, marginal osteophytes were observed from micro-CT images in all the rats at six and ten weeks post-MIA injection. The neochondrogenesis of mesenchymal stem cells in the periosteum and synovial lining has been suggested to be the precursor for osteophyte formation . It is still unclear if osteophytes are simply a pathological phenomenon or a functional adaptation in OA. Macroscopic UV illumination of the MIA-injected knee indicated accumulation of fluorochrome labels along the tibial joint margins and beneath the articular cartilage, demonstrating active osteophyte and subchondral bone formation in all the rats (Figure 8). Such calcein label accumulation was reported previously in an ACLT model for OA in rats . Further histomorphometric analysis of fluorochrome double labels is required to elucidate the rate of bone turnover in tibial subchondral trabecular bone in the MIA-injected knee and control knee.
In the present study, we documented histological changes in the cartilage of the medial tibial plateau at ten weeks post-MIA injection, including loss of proteoglycans, chondrocyte necrosis, chondrocyte proliferation, chondrone formation, cartilage fibrillation and delamination (Figure 9). Similar cartilage changes have been reported in other animal models of OA [33, 34]. In this study, articular cartilage damage was analyzed only at the end of the study (ten weeks). Analysis of cartilage changes at two and six weeks would have provided a longitudinal correlation between cartilage loss and subchondral bone changes. However, the main aim of this study was to track the changes in subchondral trabecular bone architecture over time. Moreover, we used a longitudinal study design that allows monitoring of bone changes over time in the same animal, and thus minimizes the number of rats required compared to a cross-sectional study design [5, 6].
To our knowledge, this is the first study to show serum levels of CRP in the low-dose MIA induced OA in rats. CRP is an acute phase protein and is a useful non-specific marker of inflammatory diseases . In our study, we have shown that the serum CRP levels of MIA-injected rats do not differ significantly between the baseline and subsequent time points. In addition, there was no significant difference in CRP levels between the low-dose (0.2 mg) MIA-injected rats and control rats at any time point. This demonstrates that a single intra-articular injection of low-dose MIA does not induce marked systemic inflammation in this animal model of OA. Some studies indicated that in human OA the extent and severity of OA is associated with low-grade systemic inflammation with elevated serum CRP levels . However, more recently, the Rotterdam Study-I, the largest cohort study to date, concluded that acute systemic inflammation is not present in OA and future studies should focus on the local inflammation process involved in OA .
It is hypothesized that in OA, cartilage matrix breakdown causes synovial inflammation and subsequent changes in the knee joint . In the low-dose MIA rat model, the cartilage breakdown products could lead to mild local inflammation and synovitis in the knee joint that promotes subchondral bone changes. In our study, we were unable to observe for the presence of infiltrated local inflammatory cells as histology was performed only on the tibia and not the whole knee joint. Previous studies using the high-dose MIA rat model have reported the presence of acute inflammation characterized by expansion of the synovial membrane with infiltrating macrophages, neutrophils and plasma cells in the rat's knee joint one day after injection which resolved by day seven [19, 28]. In a more recent study, increased activation of macrophages in the knee joint was reported in a high-dose MIA (1 mg) rat model up to four weeks after injection .
Although the low-dose MIA model mimics articular cartilage and subchondral bone pathology of human OA, like any other animal model of OA it does not fully mirror human OA. Barve et al. (2007) reported that 0.2 mg MIA induced a consistent matrix loss of approximately 35%, similar to the observed range of human OA samples. However, they found that the transcriptional similarity between the MIA rat and human OA cartilage was modest . This modest similarity between rat and human cartilage could have been due to a difference in sampling site, sampling of lesion and non-lesion containing cartilage, stages of OA, and contamination of cartilage by underlying bone. Moreover, this study did not look at the protein expression or post translational modification that may demonstrate greater similarity between MIA rat and human OA cartilage. Other factors such as species variability, tissue heterogeneity and differences in underlying molecular mechanisms need to be considered. The choice of an animal model of OA mainly depends on the purpose of a study. The main purpose of our study was to characterize a non-trauma animal model that mimics tissue-level features of human OA, which could be used to study the effect of disease modifying OA drugs on cartilage and subchondral bone.
In summary, the changes in cartilage and subchondral trabecular bone structure observed in the low-dose MIA rat model reveal important pathologic features of human OA and the temporal progression of the disease in the tibial subchondral bone. The low-dose MIA induced OA rat model mimics the human disease condition and clearly demonstrates disease progression in the tibial subchondral bone in a timely manner. This animal model is suitable to study the effect of suitable therapeutic drugs on cartilage and subchondral bone. In vivo micro-CT enabled the temporal characterization of the changes in subchondral bone architecture both quantitatively and qualitatively in 3D. The changes in subchondral trabecular bone structure were found to be consistent with disease progression, as confirmed by end-stage histology. In vivo micro-CT is a non-destructive imaging technique that can be used in future studies to track changes in subchondral bone structure in drug intervention studies designed to slow the progression of OA in a non-trauma low-dose MIA induced OA rat model.
anterior cruciate ligament transection
analysis of variance
bone volume fraction
disease modifying osteoarthritis drugs
micro computed tomography
Osteoarthritis Research Society International
region of interest
volumetric bone mineral density
volume of interest
The authors wish to thank Dr Sander M. Botter (Erasmus Medical Centre, Rotterdam, The Netherlands) for kindly providing the software for the automatic segmentation of subchondral plate and trabecular bone. The authors thank Ms Cheryl Gan for preparation of the histology slides, Ms Lena Truong for assistance with animal dissection, Dr Dorota Gancarz for assistance with the animal model, Dr Allan Rofe for kindly providing the MIA, the IMVS animal care facility staff, and Adelaide Microscopy staff. The authors also wish to acknowledge the support of the Bone and Joint Research Laboratory staff and funding from Endeavour postgraduate scholarship from the Australian Government, Department of Education, Employment, and Workplace Relations (DEEWR).
- Bailey AJ, Mansell JP, Sims TJ, Banse X: Biochemical and mechanical properties of subchondral bone in osteoarthritis. Biorheology. 2004, 41: 349-358.PubMedGoogle Scholar
- Kalbhen DA: Chemical model of osteoarthritis--a pharmacological evaluation. J Rheumatol. 1987, 14 (Spec No): 130-131.PubMedGoogle Scholar
- Guingamp C, Gegout-Pottie P, Philippe L, Terlain B, Netter P, Gillet P: Mono-iodoacetate-induced experimental osteoarthritis: a dose-response study of loss of mobility, morphology, and biochemistry. Arthritis Rheum. 1997, 40: 1670-1679. 10.1002/art.1780400917.View ArticlePubMedGoogle Scholar
- Janusz MJ, Hookfin EB, Heitmeyer SA, Woessner JF, Freemont AJ, Hoyland JA, Brown KK, Hsieh LC, Almstead NG, De B, Natchus MG, Pikul S, Taiwo YO: Moderation of iodoacetate-induced experimental osteoarthritis in rats by matrix metalloproteinase inhibitors. Osteoarthritis Cartilage. 2001, 9: 751-760. 10.1053/joca.2001.0472.View ArticlePubMedGoogle Scholar
- Boyd SK, Davison P, Muller R, Gasser JA: Monitoring individual morphological changes over time in ovariectomized rats by in vivo micro-computed tomography. Bone. 2006, 39: 854-862. 10.1016/j.bone.2006.04.017.View ArticlePubMedGoogle Scholar
- Perilli E, Le V, Ma B, Salmon P, Reynolds K, Fazzalari NL: Detecting early bone changes using in vivo micro-CT in ovariectomized, zoledronic acid-treated, and sham-operated rats. Osteoporos Int. 2010, 21: 1371-1382. 10.1007/s00198-009-1082-z.View ArticlePubMedGoogle Scholar
- Waarsing JH, Day JS, van der Linden JC, Ederveen AG, Spanjers C, De Clerck N, Sasov A, Verhaar JA, Weinans H: Detecting and tracking local changes in the tibiae of individual rats: a novel method to analyse longitudinal in vivo micro-CT data. Bone. 2004, 34: 163-169. 10.1016/j.bone.2003.08.012.View ArticlePubMedGoogle Scholar
- Koh YH, Hong SH, Kang HS, Chung CY, Koo KH, Chung HW, Cha JH, Son KR: The effects of bone turnover rate on subchondral trabecular bone structure and cartilage damage in the osteoarthritis rat model. Rheumatol Int. 2010, 30: 1165-1171. 10.1007/s00296-009-1118-x.View ArticlePubMedGoogle Scholar
- Kalff KM, El Mouedden M, van Egmond J, Veening J, Joosten L, Scheffer GJ, Meert T, Vissers K: Pre-treatment with capsaicin in a rat osteoarthritis model reduces the symptoms of pain and bone damage induced by monosodium iodoacetate. Eurn J Pharmacol. 2010, 641: 108-113. 10.1016/j.ejphar.2010.05.022.View ArticleGoogle Scholar
- Vermeirsch H, Biermans R, Salmon PL, Meert TF: Evaluation of pain behavior and bone destruction in two arthritic models in guinea pig and rat. Pharmacol Biochem Behav. 2007, 87: 349-359. 10.1016/j.pbb.2007.05.010.View ArticlePubMedGoogle Scholar
- Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Muller R: Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res. 2010, 25: 1468-1486. 10.1002/jbmr.141.View ArticlePubMedGoogle Scholar
- Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR: Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987, 2: 595-610.View ArticlePubMedGoogle Scholar
- Botter SM, van Osch GJ, Clockaerts S, Waarsing JH, Weinans H, van Leeuwen JP: Osteoarthritis induction leads to early and temporal subchondral plate porosity in the tibial plateau of mice: an in vivo microfocal computed tomography study. Arthritis Rheum. 2011, 63: 2690-2699. 10.1002/art.30307.View ArticlePubMedGoogle Scholar
- Pritzker KP, Gay S, Jimenez SA, Ostergaard K, Pelletier JP, Revell PA, Salter D, van den Berg WB: Osteoarthritis cartilage histopathology: grading and staging. Osteoarthritis Cartilage. 2006, 14: 13-29. 10.1016/j.joca.2005.07.014.View ArticlePubMedGoogle Scholar
- Holm S: A Simple Sequentially Rejective Multiple Test Procedure. Scand J Statistics. 1979, 6: 65-70.Google Scholar
- Hayami T, Pickarski M, Wesolowski GA, McLane J, Bone A, Destefano J, Rodan GA, Duong le T: The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. Arthritis Rheum. 2004, 50: 1193-1206. 10.1002/art.20124.View ArticlePubMedGoogle Scholar
- Dedrick DK, Goldstein SA, Brandt KD, O'Connor BL, Goulet RW, Albrecht M: A longitudinal study of subchondral plate and trabecular bone in cruciate-deficient dogs with osteoarthritis followed up for 54 months. Arthritis Rheum. 1993, 36: 1460-1467. 10.1002/art.1780361019.View ArticlePubMedGoogle Scholar
- Botter SM, van Osch GJ, Waarsing JH, Day JS, Verhaar JA, Pols HA, van Leeuwen JP, Weinans H: Quantification of subchondral bone changes in a murine osteoarthritis model using micro-CT. Biorheology. 2006, 43: 379-388.PubMedGoogle Scholar
- Bove SE, Calcaterra SL, Brooker RM, Huber CM, Guzman RE, Juneau PL, Schrier DJ, Kilgore KS: Weight bearing as a measure of disease progression and efficacy of anti-inflammatory compounds in a model of monosodium iodoacetate-induced osteoarthritis. Osteoarthritis Cartilage. 2003, 11: 821-830. 10.1016/S1063-4584(03)00163-8.View ArticlePubMedGoogle Scholar
- Burr DB: The importance of subchondral bone in osteoarthrosis. Curr Opin Rheumatol. 1998, 10: 256-262. 10.1097/00002281-199805000-00017.View ArticlePubMedGoogle Scholar
- Morenko BJ, Bove SE, Chen L, Guzman RE, Juneau P, Bocan TM, Peter GK, Arora R, Kilgore KS: In vivo micro computed tomography of subchondral bone in the rat after intra-articular administration of monosodium iodoacetate. Contemp Top Lab Anim Sci. 2004, 43: 39-43.PubMedGoogle Scholar
- McErlain DD, Appleton CT, Litchfield RB, Pitelka V, Henry JL, Bernier SM, Beier F, Holdsworth DW: Study of subchondral bone adaptations in a rodent surgical model of OA using in vivo micro-computed tomography. Osteoarthritis Cartilage. 2008, 16: 458-469. 10.1016/j.joca.2007.08.006.View ArticlePubMedGoogle Scholar
- Intema F, Hazewinkel HA, Gouwens D, Bijlsma JW, Weinans H, Lafeber FP, Mastbergen SC: In early OA, thinning of the subchondral plate is directly related to cartilage damage: results from a canine ACLT-meniscectomy model. Osteoarthritis Cartilage. 2010, 18: 691-698. 10.1016/j.joca.2010.01.004.View ArticlePubMedGoogle Scholar
- Sniekers YH, Intema F, Lafeber FP, van Osch GJ, van Leeuwen JP, Weinans H, Mastbergen SC: A role for subchondral bone changes in the process of osteoarthritis; a micro-CT study of two canine models. BMC Musculoskelet Disord. 2008, 9: 20-10.1186/1471-2474-9-20.PubMed CentralView ArticlePubMedGoogle Scholar
- Fahlgren A, Messner K, Aspenberg P: Meniscectomy leads to an early increase in subchondral bone plate thickness in the rabbit knee. Acta Orthop Scand. 2003, 74: 437-441. 10.1080/00016470310017758.View ArticlePubMedGoogle Scholar
- Layton MW, Goldstein SA, Goulet RW, Feldkamp LA, Kubinski DJ, Bole GG: Examination of subchondral bone architecture in experimental osteoarthritis by microscopic computed axial tomography. Arthritis Rheum. 1988, 31: 1400-1405. 10.1002/art.1780311109.View ArticlePubMedGoogle Scholar
- Buckland-Wright C: Subchondral bone changes in hand and knee osteoarthritis detected by radiography. Osteoarthritis Cartilage. 2004, 12 (Suppl A): S10-19.View ArticlePubMedGoogle Scholar
- Guzman RE, Evans MG, Bove S, Morenko B, Kilgore K: Mono-iodoacetate-induced histologic changes in subchondral bone and articular cartilage of rat femorotibial joints: an animal model of osteoarthritis. Toxicol Pathol. 2003, 31: 619-624.View ArticlePubMedGoogle Scholar
- Ondrouch AS: Cyst formation in osteoarthritis. J Bone Joint Surg Br. 1963, 45: 755-760.PubMedGoogle Scholar
- Bancroft LW, Peterson JJ, Kransdorf MJ: Cysts, geodes, and erosions. Radiol Clin North Am. 2004, 42: 73-87. 10.1016/S0033-8389(03)00165-9.View ArticlePubMedGoogle Scholar
- Tanamas SK, Wluka AE, Pelletier JP, Martel-Pelletier J, Abram F, Wang Y, Cicuttini FM: The association between subchondral bone cysts and tibial cartilage volume and risk of joint replacement in people with knee osteoarthritis: a longitudinal study. Arthritis Res Ther. 2010, 12: R58-10.1186/ar2971.PubMed CentralView ArticlePubMedGoogle Scholar
- van der Kraan PM, van den Berg WB: Osteophytes: relevance and biology. Osteoarthritis Cartilage. 2007, 15: 237-244. 10.1016/j.joca.2006.11.006.View ArticlePubMedGoogle Scholar
- Bendele AM: Animal models of osteoarthritis. J Musculoskelet Neuronal Interact. 2001, 1: 363-376.PubMedGoogle Scholar
- Hayami T, Pickarski M, Zhuo Y, Wesolowski GA, Rodan GA, Duong le T: Characterization of articular cartilage and subchondral bone changes in the rat anterior cruciate ligament transection and meniscectomized models of osteoarthritis. Bone. 2006, 38: 234-243. 10.1016/j.bone.2005.08.007.View ArticlePubMedGoogle Scholar
- Pepys MB, Hirschfield GM: C-reactive protein: a critical update. J Clin Invest. 2003, 111: 1805-1812.PubMed CentralView ArticlePubMedGoogle Scholar
- Sturmer T, Brenner H, Koenig W, Gunther KP: Severity and extent of osteoarthritis and low grade systemic inflammation as assessed by high sensitivity C reactive protein. Ann Rheum Dis. 2004, 63: 200-205. 10.1136/ard.2003.007674.PubMed CentralView ArticlePubMedGoogle Scholar
- Kerkhof HJ, Bierma-Zeinstra SM, Castano-Betancourt MC, de Maat MP, Hofman A, Pols HA, Rivadeneira F, Witteman JC, Uitterlinden AG, van Meurs JB: Serum C reactive protein levels and genetic variation in the CRP gene are not associated with the prevalence, incidence or progression of osteoarthritis independent of body mass index. Ann Rheum Dis. 2010, 69: 1976-1982. 10.1136/ard.2009.125260.View ArticlePubMedGoogle Scholar
- Martel-Pelletier J: Pathophysiology of osteoarthritis. Osteoarthritis Cartilage. 2004, 12 (Suppl A): S31-33.View ArticlePubMedGoogle Scholar
- Piscaer TM, Muller C, Mindt TL, Lubberts E, Verhaar JA, Krenning EP, Schibli R, De Jong M, Weinans H: Imaging of activated macrophages in experimental osteoarthritis using folate-targeted animal single-photon-emission computed tomography/computed tomography. Arthritis Rheum. 2011, 63: 1898-1907. 10.1002/art.30363.View ArticlePubMedGoogle Scholar
- Barve RA, Minnerly JC, Weiss DJ, Meyer DM, Aguiar DJ, Sullivan PM, Weinrich SL, Head RD: Transcriptional profiling and pathway analysis of monosodium iodoacetate-induced experimental osteoarthritis in rats: relevance to human disease. Osteoarthritis Cartilage. 2007, 15: 1190-1198. 10.1016/j.joca.2007.03.014.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.